An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC)

Trial Profile

An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Angiomyolipoma; Tuberous sclerosis
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 11 Oct 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 05 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top